Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease

OBJECTIVE: The SENSCIS(®) trial demonstrated a significant reduction of lung function decline in patients with SSc-associated interstitial lung disease (SSc-ILD) treated with nintedanib, but no significant effect on health-related quality of life (HRQoL). To assess whether SSc/SSc-ILD severity and l...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreuter, Michael, Hoffmann-Vold, Anna-Maria, Matucci-Cerinic, Marco, Saketkoo, Lesley Ann, Highland, Kristin B, Wilson, Hilary, Alves, Margarida, Erhardt, Elvira, Schoof, Nils, Maher, Toby M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910566/
https://www.ncbi.nlm.nih.gov/pubmed/35640959
http://dx.doi.org/10.1093/rheumatology/keac325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910566/
https://www.ncbi.nlm.nih.gov/pubmed/35640959
http://dx.doi.org/10.1093/rheumatology/keac325

Ejemplares similares